Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,107 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Cutaneous T-cell-attracting chemokine as a novel biomarker for predicting prognosis of idiopathic pulmonary fibrosis: a prospective observational study.
Niwamoto T, Handa T, Murase Y, Nakatsuka Y, Tanizawa K, Taguchi Y, Tomioka H, Tomii K, Kita H, Uyama M, Tsuchiya M, Emura M, Kawamura T, Arai N, Arita M, Uno K, Yoshizawa A, Uozumi R, Yamaguchi I, Matsuda F, Chin K, Hirai T. Niwamoto T, et al. Among authors: arita m. Respir Res. 2021 Jun 17;22(1):181. doi: 10.1186/s12931-021-01779-9. Respir Res. 2021. PMID: 34158044 Free PMC article.
[Multicenter screening of Chlamydia pneumoniae pneumonia by ELISA method].
Ishida T, Hashimoto T, Arita M, Ito I, Ishihara K, Okazaki M, Taguchi Y. Ishida T, et al. Among authors: arita m. Kansenshogaku Zasshi. 1999 Jan;73(1):70-5. doi: 10.11150/kansenshogakuzasshi1970.73.70. Kansenshogaku Zasshi. 1999. PMID: 10077904 Clinical Trial. Japanese.
Composite Physiologic Index, Percent Forced Vital Capacity and Percent Diffusing Capacity for Carbon Monoxide Could Be Predictors of Pirfenidone Tolerability in Patients with Idiopathic Pulmonary Fibrosis.
Konishi S, Arita M, Ito I, Tachibana H, Takaiwa T, Fukuda Y, Watanabe N, Tsubouchi K, Masuda G, Tanaka M, Kourogi Y, Kunimasa K, Nishiyama A, Iwasaku M, Ito A, Tokioka F, Yoshioka H, Hashimoto T, Ishida T. Konishi S, et al. Among authors: arita m. Intern Med. 2015;54(22):2835-41. doi: 10.2169/internalmedicine.54.4118. Epub 2015 Nov 15. Intern Med. 2015. PMID: 26567995 Free article.
Comparison of clinical and pathological features of lung lesions of systemic IgG4-related disease and idiopathic multicentric Castleman's disease.
Terasaki Y, Ikushima S, Matsui S, Hebisawa A, Ichimura Y, Izumi S, Ujita M, Arita M, Tomii K, Komase Y, Owan I, Kawamura T, Matsuzawa Y, Murakami M, Ishimoto H, Kimura H, Bando M, Nishimoto N, Kawabata Y, Fukuda Y, Ogura T; Tokyo Diffuse Lung Diseases Study Group. Terasaki Y, et al. Among authors: arita m. Histopathology. 2017 Jun;70(7):1114-1124. doi: 10.1111/his.13186. Epub 2017 Apr 3. Histopathology. 2017. PMID: 28207938
Clinical spectrum and prognostic factors of possible UIP pattern on high-resolution CT in patients who underwent surgical lung biopsy.
Kondoh Y, Taniguchi H, Kataoka K, Furukawa T, Shintani A, Fujisawa T, Suda T, Arita M, Baba T, Ichikado K, Inoue Y, Kishi K, Kishaba T, Nishiyama O, Ogura T, Tomii K, Homma S. Kondoh Y, et al. Among authors: arita m. PLoS One. 2018 Mar 28;13(3):e0193608. doi: 10.1371/journal.pone.0193608. eCollection 2018. PLoS One. 2018. PMID: 29590152 Free PMC article.
Thrombomodulin Alfa for Acute Exacerbation of Idiopathic Pulmonary Fibrosis. A Randomized, Double-Blind Placebo-controlled Trial.
Kondoh Y, Azuma A, Inoue Y, Ogura T, Sakamoto S, Tsushima K, Johkoh T, Fujimoto K, Ichikado K, Matsuzawa Y, Saito T, Kishi K, Tomii K, Sakamoto N, Aoshima M, Araya J, Izumi S, Arita M, Abe M, Yamauchi H, Shindoh J, Suda T, Okamoto M, Ebina M, Yamada Y, Tohda Y, Kawamura T, Taguchi Y, Ishii H, Hashimoto N, Abe S, Taniguchi H, Tagawa J, Bessho K, Yamamori N, Homma S. Kondoh Y, et al. Among authors: arita m. Am J Respir Crit Care Med. 2020 May 1;201(9):1110-1119. doi: 10.1164/rccm.201909-1818OC. Am J Respir Crit Care Med. 2020. PMID: 31917621 Clinical Trial.
Impact of bronchoalveolar lavage lymphocytosis on the effects of anti-inflammatory therapy in idiopathic non-specific interstitial pneumonia, idiopathic pleuroparenchymal fibroelastosis, and unclassifiable idiopathic interstitial pneumonia.
Yamagata A, Arita M, Tachibana H, Tokioka F, Sugimoto C, Sumikawa H, Tanaka T, Yasui H, Fujisawa T, Nakamura Y, Suda T, Ishida T. Yamagata A, et al. Among authors: arita m. Respir Res. 2021 Apr 20;22(1):115. doi: 10.1186/s12931-021-01726-8. Respir Res. 2021. PMID: 33879137 Free PMC article.
Long-term effect of pulmonary rehabilitation in idiopathic pulmonary fibrosis: a randomised controlled trial.
Kataoka K, Nishiyama O, Ogura T, Mori Y, Kozu R, Arizono S, Tsuda T, Tomioka H, Tomii K, Sakamoto K, Ishimoto H, Kagajo M, Ito H, Ichikado K, Sasano H, Eda S, Arita M, Goto Y, Hataji O, Fuke S, Shintani R, Hasegawa H, Ando M, Ogawa T, Shiraishi M, Watanabe F, Nishimura K, Sasaki T, Miyazaki S, Saka H, Kondoh Y; FITNESS study Collaborators. Kataoka K, et al. Among authors: arita m. Thorax. 2023 Aug;78(8):784-791. doi: 10.1136/thorax-2022-219792. Epub 2023 Apr 3. Thorax. 2023. PMID: 37012071 Clinical Trial.
1,107 results